cdifffoundation.org
Synthetic Biologics SYN-004 (ribaxamase) Achieves Primary Endpoint in Phase 2b Trial for C. difficile Infection
Synthetic Biologics’ SYN-004 (ribaxamase) Achieves Primary Endpoint in Phase 2b Trial for C. difficile Infection (CDI) Synthetic Biologics, Inc. a late-stage clinical company developin…